# US 2019/0315709 A1 · 4-amino-2-pyrido-bicyclic pyrimidines and use thereof as topoisomerase ii inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315709 A1
- Document ID: US20190315709A1
- Status: Published application
- Kind: A1
- Application number: 16/472,593
- Filed: 2017-12-15
- Published: 2019-10-17
- Earliest claimed: 2016-12-23
- Assignees: Fondazione Istituto Italiano Di Tecnologia; Alma Mater Studiorum - Università di Bologna; Universita' Degli Studi Di Padova
- Applicants: Fondazione Istituto Italiano Di Tecnologia; Alma Mater Studiorum - Universita' Di Bologna; Universita' Degli Studi Di Padova
- Inventors: Marco DE VIVO; Jose Antonio ORTEGA MARTINEZ; Jose Manuel ARENCIBIA JIMENEZ; Anna MINARINI; Claudia SISSI
- Web page: https://patentgrep.com/patent/US20190315709A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns 4-amino-2-pyrido-bicyclic pyrimidines as type II topoisomerase inhibitors and use thereof as medicaments especially in the treatment of cancer. The invention also provides a method for the manufacture of 4-amino-2-pyrido bicyclic pyrimidines.

## Claims

### Claim 1

A compound of formula (I)
an enantiomer, or a pharmaceutically acceptable salt thereof,
wherein
R═H, halogen, C1-6 alkyl, C1-6 alkoxy, OH, CF3, NR″R′″;
R′ H, C1-6 alkyl,
X is H, C1-6 alkyl, C1-6 alkoxy, NR″R′″, C1-6 alkylalkoxy, C1-C6 alkylamide;
R″R′″ are, independently, H, C1-6 alkyl, C1-6 alkylalkoxy or may form a 4 to 7-membered heterocyclic ring together with the nitrogen atom to which they are connected,
for use in treating cancer.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein
R is halogen,
R′═H or C1-6 alkyl, preferably is H
R″R′″ are independently, H, C1-6 alkyl or C1-C6 alkylalkoxy, preferably are H.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein
R═halogen, C1-6 alkyl, C1-6 alkoxy, OH, CF3, NR″R′″, preferably is halogen or OH;
R′═H, C1-6 alkyl, preferably is H;
X═H, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylalkoxy, C1-C6 alkylamide, preferably is H;
R″R′″ are, independently, H, C1-6 alkyl, C1-6 alkylalkoxy, preferably are H.

### Claim 4 (depends on 1)

The compound according to claim 1 having Formula (Ia)
wherein R═H, halogen, C1-6 alkyl, C1-6 alkoxy, OH, CF3, NR″R′″ and
R′═H, C1-6 alkyl;
R″R′″ are, independently, H, C1-6 alkyl, C1-C6 alkylalkoxy or may form a 4 to 7-membered heterocyclic ring together with the nitrogen atom to which they are connected.

### Claim 5 (depends on 4)

The compound of Formula (Ia) according to claim 4 wherein R″R′″ are H and optionally R′ is H.

### Claim 6 (depends on 1)

The compound according to claim 1 having Formula (Ib)
wherein R═H, halogen, C1-6 alkyl, C1-6 alkoxy, OH, CF3, NR″R′″ and
R′═H, C1-6 alkyl;
X is H, C1-6, alkyl, C1-6 alkylalkoxy.

### Claim 7 (depends on 6)

The compound according to claim 6 wherein X is H and optionally R′ is H.

### Claim 8

A compound of Formula (Ia)
wherein R═H, C1-6 alkyl, C1-6 alkoxy, OH, NR″R′″ and
R′═H, C1-6 alkyl;
R″R′″ are, independently, H, C1-6 alkyl, C1-C6 alkylalkoxy or may form a 4 to 7-membered heterocyclic ring together with the nitrogen atom to which they are connected.

### Claim 9 (depends on 8)

The compound of Formula (Ia) according to claim 8, wherein R″R′″ are H and optionally R′ is H.

### Claim 10 (depends on 8)

The compound of Formula (Ia) according to claim 8 which is selected from the group consisting of
N4-(m-tolyl)-2-(4-pyridyl)-5,6,7,8-tetrahydroquinazoline-4,6-diamine (E1.4)
N4-(3-methoxyphenyl)-2-(4-pyridyl)-5,6,7,8-tetrahydroquinazoline-4,6-diamine (E1.5)
N4-(3-aminophenyl)-2-(4-pyridyl)-5,6,7,8-tetrahydroquinazoline-4,6-diamine (E1.6)
N4-[3-(methylamino)phenyl]-2-(4-pyridyl)-5,6,7,8-tetrahydroquinazoline-4,6-diamine (E1.7)
4-[[6-amino-2-(4-pyridyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amino]phenol (E1.9)
N4-(3-fluorophenyl)-2-(3-pyridyl)-5,6,7,8-tetrahydroquinazoline-4,6-diamine (E1.10)
N4-[4-(dimethylamino)phenyl]-2-(4-pyridyl)-5,6,7,8-tetrahydroquinazoline-4,6-diamine (E1.11).

### Claim 11

A compound of Formula (Ib)
wherein R═H, Cl, C1-6 alkyl, OH, CF3, NR″R′″,
R′═H, C1-6 alkyl;
X═H, C1-6 alkyl, C1-6 alkoxy, NR″R′″, C1-6 alkylalkoxy, C1-C6 alkylamide.

### Claim 12 (depends on 11)

The compound of Formula (Ib) according to claim 11 which is selected from the group consisting of
N1-[2-(4-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]benzene-1,3-diamine (E2.3),
N3-methyl-N1-[2-(4-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]benzene-1,3-diamine (E2.4),
N3,N3-dimethyl-N1-[2-(4-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]benzene-1,3-diamine (E2.5),
4-[[2-(4-pyridyl)-5,6,7,8-tetrahydro[4,3-d]pyrimidin-4-yl]amino]phenol (E2.6),
N-(2-fluorophenyl)-2-(4-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (E2.7).

### Claim 13 (depends on 1)

The compound according to claim 1 which is N4-(3-fluorophenyl)-2-(4-pyridyl)quinazoline-4,6-diamine (E3) or N-(3-fluorophenyl)-2-(4-pyridyl)pyrido[4,3-d]pyrimidin-4-amine (E4).

### Claim 14 (depends on 8)

The compound according to claim 8 for use as a medicament, in particular in the treatment of cancer.

### Claim 15 (depends on 1)

Compound according to claim 1 for use in the treatment of cancer in combination with an antitumoral agent.

### Claim 16 (depends on 15)

The compound for use according to claim 15 wherein the antitumoral agent is selected from doxorubicin, daunorubicin, etoposide, cisplatin, oxaliplatin, carboplatin, gemcitabine, 5-fluorouracil, capecitabine, tegafur-uracil (UFT), dacarbazine, fenretinide, camptothecin, irinotecan, fludarabine, vinblastine, taxol, mitomycin C.

### Claim 17 (depends on 1)

The compound for use according to claim 1 wherein the cancer is lung cancer, prostate cancer colorectal cancer, liver cancer, head and neck cancer, breast cancer, choriocarcinoma, ovarian and testicular cancers, lymphoma, and acute myeloid leukemia, central nervous system tumors, malignant lymphoma and bladder cancer, metastatic melanoma, precancerous skin conditions such as actinic keratosis, skin cancers such as squamous cell carcinoma and basal cell carcinoma, and hematological malignancies such as chronic myelogenous leukemia.

### Claim 18 (depends on 4)

A method for the manufacture of a compound of formula (Ia) according to claim 4 comprising the steps A to E according to the following reaction scheme
wherein
step A comprises the addition of urea, MeONa in a C1-C4 alcohol
step B comprises the addition of POCl3 to give a solution which is evaporated to give a residue
step C comprises the addition of aniline and diisopropylethylamine in a C1-C4 alcohol
step D comprises the addition of boronic acid PdCl2(dppf)dichloromethane complex and an aqueous solution of K2CO3 in 1,4-dioxane
step E comprises the addition of ammonium formate, Pd(OH)2—C, a C1-C4 alcohol.

### Claim 19

A method for the manufacture of a compound of formula E3 comprising the steps C to E according to the following reaction scheme
wherein
step A comprises the addition of urea
step B comprises the addition of PCl5 in POCl3
step C comprises the addition of 3-fluoroaniline, diisopropylethylamine
step D comprises the addition of PdCl2(dppf) dichloromethane complex and K2CO3 aqueous solution in 1,4-dioxane
step E comprises the addition of ammonium formate (4 mmol), Pd(OH)2—C.

### Claim 20 (depends on 1)

A method for the manufacture of a compound of formula (I) according to claim 1 comprising steps A to D according to the following reaction scheme:
comprising
a step A comprising reacting i) a cyclic 2-oxo ethylester or ii) 4-Amino-nicotinic acid with pyridinecarboxamidine hydrochloride, to obtain a 2-pyrido-4-pyrimidone fused ring,
a step B of clorination by reacting under N2 atmosphere the 2-pyrido-4-pyrimidone fused ring of step A either with
iii) POCl3, or
iv) PCl5 and POCl3
to obtain a 2-chloro-4-pyrido-pyrimidine fused ring,
a step C of aniline introduction by reacting the 2-chloro-4-pyrido-pyrimidine fused ring of step B with a substituted aniline and Cs2CO3,
a step D of deprotection by reacting the product obtained by step C with ammonium formate in presence of a catalyst.
